RayKnowChina Research Map
Shortlist0

RecruitingHepatocellular carcinomaPhase 3

Registered title, quoted from ClinicalTrials.gov

DEB-TACE vs cTACE in HCC After TIPS

An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by First Affiliated Hospital of Sun Yat-sen University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorFirst Affiliated Hospital of Sun Yat-sen University中山大学附属第一医院GuangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07322848, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 3

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (3 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. co-infection with HIV or syphilis.

    Exclusion criterion 8

    concurrent other malignancy or history of other malignancy within the past 5 years.

    Exclusion criterion 9

  3. pregnancy, breastfeeding, or planning pregnancy within 2 years.

    Exclusion criterion 7

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07322848, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • histologically or clinically confirmed primary hepatocellular carcinoma, beyond Milan criteria (single lesion >5 cm OR ≥3 lesions with at least one ≥3 cm). At least one intrahepatic measurable lesion with tumor burden ≤50%, no distant metastasis. No prior antitumor therapy within 12 months before enrollment.
  • underwent TIPS procedure for secondary prevention of variceal bleeding or refractory ascites. Confirmed patent TIPS at 1-month follow-up with portosystemic blood flow visible throughout the shunt and Doppler velocity > 60 cm/s.
  • child-Pugh class A or B.
  • estimated survival ≥3 months.
  • adequate organ function:Neutrophils ≥1.5 × 10⁹/L; Platelets ≥50 × 10⁹/L; Hemoglobin ≥90 g/L; Serum albumin ≥30 g/L; Bilirubin ≤50 μmol/L; AST/ALT ≤5 × upper limit of normal (ULN), ALP ≤4 × ULN; INR ≤2.3; Creatinine ≤1.5 × ULN.

Exclusion Criteria:

  • diffuse hepatic infiltration, unassessable lesions on imaging, or tumor burden >50%.
  • simultaneous portal vein branch tumor thrombus or main portal vein tumor thrombus.
  • underwent liver transplantation or antitumor therapy after TIPS placement.
  • contraindications to TACE (e.g., portosystemic shunt, hepatofugal blood flow, significant atherosclerosis).
  • presence of brain metastases.
  • Allergy to contrast agents.
  • pregnancy, breastfeeding, or planning pregnancy within 2 years.
  • co-infection with HIV or syphilis.
  • concurrent other malignancy or history of other malignancy within the past 5 years.
  • severe cardiac, renal, or other organ dysfunction.
  • active clinically severe infection > Grade 2 (per NCI-CTC v5.0).
  • psychiatric/psychological conditions that may impair informed consent.
  • participation in other drug clinical trials within 12 months prior to enrollment.

Quoted from ClinicalTrials.gov, NCT07322848, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07322848, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07322848